Search clinical trials for: BI 655066 (low medium i.v. dose)

Total 309 results

AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Boehringer Ingelheim

Completed

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

Lupus Nephritis

Spain, United Kingdom, United States, Canada, Thailand, Germany, Italy, Japan, Serbia, Australia, Korea, Republic of, Mexico, Malaysia, Philippines, Poland, Portugal, Greece, Hong Kong, Czechia, France
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Boehringer Ingelheim

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Hepatitis C

Japan
Boehringer Ingelheim

Completed

Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Denmark, France, Ireland, Korea, Republic of, Portugal, United Kingdom
Alimorad Farshchian

Recruiting

Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain

Back Pain | Facet Joint Pain | Facet Joints; Degeneration

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
Peking University Third Hospital

Completed

The Efficacy and Safety of Sofadil for Injection in the Treatment of Acute Ischemic Stroke

Acute Ischemic Stroke

China
Boehringer Ingelheim

Completed

BI 44370 TA in Acute Migraine Attack

Migraine Disorders

Belgium, El Salvador, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

COVID-19

China
Danielle Kim Turgeon
PvP Biologics, Inc.

Terminated

Gastric Gluten-Degradation Activity of PvP001

Digestive System Disease

United States
Boehringer Ingelheim

Completed

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Systemic Lupus Erythematosus

United States, Korea, Republic of, Taiwan, Bulgaria, Spain, China, Argentina, Australia, Chile, Greece, Japan, Mauritius, Mexico, Moldova, Republic of, Philippines, Poland, South Africa, Colombia, Brazil, Serbia, Israel, Romania
AstraZeneca

Completed

MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients

Ulcerative Colitis

Japan
Purdue University
Alliance for Potato Research and Education

Completed

Bioavailability of Potassium From Potatoes and Potassium Gluconate (Potato)

Blood Pressure | Potassium Bioavailability

United States
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.

Withdrawn

A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)

Painful Diabetic Neuropathy

Germany, United Kingdom
Danisco
Sprim Advanced Life Sciences

Terminated

Dose-Responsive Effect of Polydextrose on Whole Gut Transit Time (PDX-Transit)

Functional Constipation

Italy
Biogen

Completed

Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

Healthy Volunteers

Australia, China
Merck Sharp & Dohme LLC

Completed

Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001)

Dengue
Biocity Biopharmaceutics Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

Diabetic Kidney Disease | IgA Nephropathy

China
University of California, Berkeley
University of California, Davis

Active, not recruiting

Moringa Powder Acceptability Trial Among Healthy Adults

Consumption | Side Effect | Acceptability

United States
Causeway Therapeutics

Completed

Safety, Tolerability, and Pharmacokinetics of Single Dose TenoMiR as a Treatment for Tennis Elbow

Tennis Elbow

United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, China, France, Germany, India, Korea, Republic of, Mexico, Slovakia, Slovenia, Taiwan, Turkey
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers

Healthy
Kolon Life Science

Completed

Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis

Degenerative Arthritis

Korea, Republic of
GlaxoSmithKline

Completed

GSK618334 Repeat Dose Study

Substance Dependence

United Kingdom
Prim. Priv. Doz. Dr. Daniel Cejka
Medice Arzneimittel Pütter GmbH & Co KG

Withdrawn

The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients

Kidney Transplant; Complications

Austria
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Recruiting

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Systemic Lupus Erythematosus

United States, Spain, China, Korea, Republic of, Argentina, Bulgaria, Chile, Greece, Japan, Mauritius, Mexico, Moldova, Republic of, Poland, South Africa, Australia, Colombia, Philippines, Serbia
Visterra, Inc.

Completed

Safety and Efficacy Study of VIS649 for IgA Nephropathy

Immunoglobulin A Nephropathy | Glomerular Disease | IgAN

United States, Australia, Canada, Hong Kong, India, Japan, Korea, Republic of, Malaysia, Philippines, Singapore, Spain, Sri Lanka, Taiwan, Thailand, United Kingdom
Pfizer
Thrombolysis In Myocardial Infarction (TIMI)

Recruiting

A Study of Ponsegromab in People With Heart Failure (GARDEN TIMI 74)

Heart Failure

United States, Canada, China, Australia, Spain, Japan, Czechia, Hungary, United Kingdom, Poland, Germany
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
OcuNexus Therapeutics, Inc.

Completed

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE) (DUNE)

Diabetic Foot Ulcers

Russian Federation, United States, Ukraine
Boehringer Ingelheim

Completed

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis
Akeso

Terminated

A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

Ovarian Neoplasms | Ovarian Cancer | Recurrent Ovarian Carcinoma | Relapsed Ovarian Cancer

China
Trinomab Biotech Co., Ltd.

Completed

Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers

Tetanus

China
AbbVie

Completed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Crohn's Disease

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Korea, Republic... and more

Search clinical trials for: BI 655066 (low medium i.v. dose)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations